Zydus Cadila gets USFDA nod to Sevelamer Carbonate Tablets for controlling phosphorus in CKD patients
It helps prevent hypocalcemia caused by elevated phosphorus.
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Sevelamer Carbonate Tablets (US RLD - Renvela Tablets) in the strength of 800 mg.
The drug is a phosphate binder and is used to control phosphorus levels in people with chronic kidney disease who are on dialysis.
It helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus.
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad. The group now has 296 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Covid-19: Zydus Cadila Unveils Remdesivir Under Brand Name Remdac For Rs 2800 Per Vial In India
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: Covid-19 Vaccine: Zydus Cadila To Begin Phase II Trials Of ZyCoV-D Today
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd